Major Depressive Disorder - Pipeline Review, H2 2016

Date: October 12, 2016
Pages: 201
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M6F916E21F2EN
Leaflet:

Download PDF Leaflet

Major Depressive Disorder - Pipeline Review, H2 2016
Major Depressive Disorder - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape.

Major depressive disorder (MDD) is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. Symptoms of MDD include agitation, restlessness, and irritability, anger, becoming withdrawn or isolated, fatigue and lack of energy, feeling hopeless and helpless, worthless, guilty, self-hate, loss of interest or pleasure in activities that were once enjoyed, sudden change in appetite, often with weight gain or loss, thoughts of death or suicide, trouble concentrating and trouble sleeping or sleeping too much.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Major Depressive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Major Depressive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 18, 11, 1, 8 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Major Depressive Disorder.

Major Depressive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Major Depressive Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Major Depressive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Major Depressive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Major Depressive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Major Depressive Disorder (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Major Depressive Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Major Depressive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Major Depressive Disorder Overview
Therapeutics Development
Major Depressive Disorder - Therapeutics under Development by Companies
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes
Major Depressive Disorder - Pipeline Products Glance
Major Depressive Disorder - Products under Development by Companies
Major Depressive Disorder - Products under Investigation by Universities/Institutes
Major Depressive Disorder - Companies Involved in Therapeutics Development
Major Depressive Disorder - Therapeutics Assessment
Drug Profiles
Major Depressive Disorder - Dormant Projects
Major Depressive Disorder - Discontinued Products
Major Depressive Disorder - Product Development Milestones
Appendix 194

LIST OF TABLES

Number of Products under Development for Major Depressive Disorder, H2 2016
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Major Depressive Disorder - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Major Depressive Disorder - Pipeline by Alkermes Plc, H2 2016
Major Depressive Disorder - Pipeline by Allergan Plc, H2 2016
Major Depressive Disorder - Pipeline by Angelini Group, H2 2016
Major Depressive Disorder - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
Major Depressive Disorder - Pipeline by BioCrea GmbH, H2 2016
Major Depressive Disorder - Pipeline by BioLite, Inc., H2 2016
Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H2 2016
Major Depressive Disorder - Pipeline by Cerecor Inc., H2 2016
Major Depressive Disorder - Pipeline by Clera Inc., H2 2016
Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
Major Depressive Disorder - Pipeline by GlaxoSmithKline Plc, H2 2016
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H2 2016
Major Depressive Disorder - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Major Depressive Disorder - Pipeline by Johnson & Johnson, H2 2016
Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H2 2016
Major Depressive Disorder - Pipeline by Les Laboratoires Servier SAS, H2 2016
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H2 2016
Major Depressive Disorder - Pipeline by Mapreg S.A.S., H2 2016
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H2 2016
Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H2 2016
Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H2 2016
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H2 2016
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H2 2016
Major Depressive Disorder - Pipeline by Saniona AB, H2 2016
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H2 2016
Major Depressive Disorder - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Major Depressive Disorder - Pipeline by TRImaran Pharma, Inc., H2 2016
Major Depressive Disorder - Pipeline by Turing Pharmaceuticals AG , H2 2016
Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Major Depressive Disorder - Dormant Projects, H2 2016
Major Depressive Disorder - Dormant Projects (Contd..1), H2 2016
Major Depressive Disorder - Dormant Projects (Contd..2), H2 2016
Major Depressive Disorder - Dormant Projects (Contd..3), H2 2016
Major Depressive Disorder - Dormant Projects (Contd..4), H2 2016
Major Depressive Disorder - Dormant Projects (Contd..5), H2 2016
Major Depressive Disorder - Dormant Projects (Contd..6), H2 2016
Major Depressive Disorder - Discontinued Products, H2 2016
Major Depressive Disorder - Discontinued Products (Contd..1), H2 2016
Major Depressive Disorder - Discontinued Products (Contd..2), H2 2016 189

LIST OF FIGURES

Number of Products under Development for Major Depressive Disorder, H2 2016
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Major Depressive Disorder - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: